2025-04-02 中国科学院(CAS)
<関連情報>
- https://english.cas.cn/newsroom/research_news/life/202504/t20250403_909247.shtml
- https://www.cell.com/matter/abstract/S2590-2385(25)00127-4
パネス細胞制御と粘液層リモデリングによる炎症性腸疾患の経口ナノ粒子療法 Oral nanoparticle therapy for inflammatory bowel disease by Paneth cell regulation and mucus layer remodeling
Yuting Qin∙ Zeming Wang∙ Hanqing Chen∙ Guangjun Nie∙ Ruifang Zhao
Matter Published:March 27, 2025
DOI:https://doi.org/10.1016/j.matt.2025.102084
Graphical abstract
Progress and potential
Traditional treatments for inflammatory bowel disease (IBD) focus on curbing excessive immune responses but often overlook the complex interplay of intestinal barrier dysfunction, microbiota disruptions, and abnormal mucosal immunity. Our research introduces tungsten-encapsulated zinc nanoparticles (W@ZnNPs) as a multifunctional therapeutic agent, outperforming conventional mesalamine and nanoadjuvants. W@ZnNPs enhance Paneth and goblet cell functions, precisely modulate Enterobacteriaceae, inhibit bacterial translocation, and decrease oxidative inflammation. Our study highlights the role of nanotherapeutics in regulating gut homeostasis, shaping the microbiome, and modulating innate immune responses, providing new insights into the treatment of inflammatory conditions.
Highlights
- Synthesized W@ZnNPs via a single-step process
- W@ZnNPs have high gastric stability and minimal side effects
- W@ZnNPs precisely modulate microbiota and intestinal cell functions
Summary
Increased intestinal permeability, gut microecology dysbiosis, and the development of inflammatory bowel disease (IBD) are closely linked. Defective Paneth cell (PC) differentiation and disrupted goblet cell (GC) mucus exacerbate intestinal inflammation, driving IBD progression. In this context, we investigated the therapeutic effects of tungsten-encapsulated zinc nanoparticles (W@ZnNPs) in murine models of IBD. W@ZnNPs, with their high gastric stability and minimal side effects, have been found to enhance the mucosal barrier by improving Paneth and goblet cell functions, thus mitigating gut microbiota dysbiosis-induced inflammation. Orally delivered, W@ZnNPs outperformed mesalamine and other nanoadjuvants in ameliorating colitis, mainly through a dual mechanism of tungsten-mediated editing of Enterobacteriaceae and zinc-mediated modulation of intestinal cells. Most importantly, W@ZnNPs hold the potential to restore host-microbe interactions, making them a promising nanotherapeutic for IBD treatment.
